Susceptibility of Cutibacterium acnes to topical minocycline foam.

Abstract excerpt

FMX101 4% minocycline foam (FMX101 4%) is a novel, topical minocycline formulation for treatment of acne vulgaris. We report that FMX101 4% had an MIC90 of 0.25 μg/ml and was ≥4-fold more active than comparator antimicrobials against a panel of 98 clinical Cutibacterium acnes isolates. The panel was diverse by clonal complex and sequence type, having 20 novel multi-locus sequence types including clonal complexes...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Anti-Bacterial Agents
• Share to Drug Resistance, Bacterial